medicine-news-1/new-survey-report-3a-primary-care-emphasis-included-in-workplace-wellness-programs--53025-3/;msg18067;topicseen

Breaking Biology Technology:Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2 Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2 Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5 New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2 New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3

[0] Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference [0] Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products [0] YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES [0] New silicon-germanium nanowires could lead to smaller, more powerful electronic devices

Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10 GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 1 GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 2 GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 3 GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 4 GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 5 GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 6 nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 6632 1 nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 6632 2 MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 1 MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 2

[0] FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology [0] Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection [0] Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab